New anti-inflammatory approaches in COPD

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 3, 2004, Pages 335-343

  Matera, Maria Gabriella ^a   Cazzola, Mario ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADALIMUMAB; ADENOSINE A2 RECEPTOR AGONIST; ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; BAY 19 8004; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIMOSIAMOSE; BINODENOSON; CERTOLIZUMAB PEGOL; CILOMILAST; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; GRC 3015; HU 1124; INFLIXIMAB; INTERLEUKIN 10; IPL 4088; LONG ACTING DRUG; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE IV INHIBITOR; PKF 241 466; PKF 242 484; RECOMBINANT INTERLEUKIN 10; REGADENOSON; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHODILATATION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SYNTHESIS; ENTERITIS; HEMATOLOGIC DISEASE; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MACROPHAGE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PSORIASIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM;

EID: 13344250392     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.013     Document Type: Review

References (44)

1. W.Q. Gan et al. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis Thorax 59 2004 574-580
2. P.J. Barnes et al. Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase Lancet 363 2004 731-733
3. 2-agonists and corticosteroids in stable COPD Chest 126 2004 220-237
4. P.J. Barnes COPD: Is there light at the end of the tunnel? Curr. Opin. Pharmacol. 4 2004 263-272
5. M.P. Ainslie et al. Characterisation of adhesion receptors mediating lymphocyte adhesion to bronchial endothelium provides evidence for a distinct lung homing pathway Thorax 57 2002 1054-1059
6. A. Noguera et al. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 158 1998 1664-1668
7. P.C. Avila et al. Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses Clin. Exp. Allergy 34 2004 77-84
8. A. Pietrzak et al. Efaluzimab in the treatment of psoriasis Ann. Univ. Mariae Curie Sklodowska [Med.] 58 2003 174-178
9. G.W. Sullivan Adenosine A2A receptor agonists as anti-inflammatory agents Curr. Opin. Investig. Drugs 4 2003 1313-1319
10. L.E. Donnelly D.F. Rogers Therapy for chronic obstructive pulmonary disease in the 21st century Drugs 63 2003 1973-1998
11. D. Spina Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease Drugs 63 2003 2575-2594
12. C.H. Compton et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study Lancet 358 2001 265-270
13. E. Gamble et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD Am. J. Respir. Crit. Care Med. 168 2003 976-982
14. S. Leitchl et al. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chromic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 165 Suppl. 2002 A229
15. G. Sturton M. Fitzgerald Phosphodiesterase 4 inhibitors for the treatment of COPD Chest 121 5 Suppl. 2002 192S-196S
16. S. Lamontagne et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey Brain Res. 920 2001 84-96
17. S.L. Jin M. Conti Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses Proc. Natl. Acad. Sci. USA 99 2002 7628-7633
18. H. Kuss et al. In vivo efficacy in airway disease models of
19. S. Takanashi et al. Interleukin-10 level in sputum is reduced in bronchial asthma COPD and in smokers Eur. Respir. J. 14 1999 309-314
20. M.C. Li S.H. He IL-10 and its related cytokines for treatment of inflammatory bowel disease World J. Gastroenterol. 10 2004 620-625
21. W.I. De Boer Cytokines and therapy in COPD: A promising combination? Chest 121 Suppl. 5 2002 209s-218s
22. H. van der Vaart et al. The effect of infliximab in patients with chronic obstructive pulmonary disease Chest 126 Suppl. 2004 840S
23. A. Trifilieff et al. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation Br. J. Pharmacol. 135 2002 1655-1664
24. J.C. Boehm et al. 1-substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency J. Med. Chem. 39 1996 3929-3937
25. J. Nyce Respirable antisense oligonucleotides: A new, third drug class targeting respiratory disease Curr. Opin. Allergy Clin. Immunol. 2 2002 533-536
26. S.R. McColl I. Clark-Lewis Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists J. Immunol. 163 1999 2829-2835
27. J.E. Pease I. Sabroe The role of interleukin-8 and its receptors in inflammatory lung disease. Implications for therapy Am. J. Respir. Med. 1 2002 19-25
28. C. Owen Chemokine receptors in airway disease: Which receptors to target? Pulm. Pharmacol. Ther. 14 2001 193-202
29. C. Horvath et al. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: Inhibitory potential depends on type of injury and leukocytes targeted Circ. Res. 90 2002 488-494
30. J. Witherington et al. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists Bioorg. Med. Chem. Lett. 11 2001 2177-2180
31. M. Saetta et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 165 2002 1404-1409
32. M. Delhase et al. Kinase regulation in inflammatory response Nature 406 2000 367-368
33. J.S. Gill et al. Effects of NFκB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line Biomaterials 23 2002 2773-2781
34. M. Bukhtiyarova et al. Improved expression, purification, and crystallization of p38α MAP kinase Protein Expr. Purif. 37 2004 154-161
35. S. Kumar et al. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases Nat. Rev. Drug Discov. 2 2003 717-726
36. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655-1657
37. 2 activates proMMP-2 through receptor tyrosine kinases/PI3-K/NF-κB pathway J. Biol. Chem. 277 2002 30271-30282
38. 4 Int. J. Biochem. Cell Biol. 30 1998 173-178
39. T. Yokomizo et al. A second leukotriene B4 receptor BLT2. A new therapeutic target in inflammation and immunological disorders J. Exp. Med. 192 2000 421-432
40. 4 Chest 123 2003 1240-1247
41. L.E. Donnelly D.F. Rogers Therapy for chronic obstructive pulmonary disease in the 21st century Drugs 63 2003 1973-1998
42. S. Kilfeather 5-Lipoxygenase inhibitors for the treatment of COPD Chest 121 5 Suppl. 2002 197S-200S
43. S. Gompertz R.A. Stockley A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD Chest 122 2002 289-294
44. B.R. Celli W. MacNee Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur. Respir. J. 23 2004 932-946